Chemotherapy Communication Magazine 
Pharmaceutical Technology
JULY 4, 2025
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Find out more Sign up for our daily news round-up!
Pharmaceutical Technology
JULY 1, 2025
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up for our daily news round-up!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 1, 2025
In June 2025, the European Commission authorised Takeda’s Adcetris (brentuximab vedotin), an antibody-drug conjugate, combined with chemotherapy for treating adults who are newly diagnosed with Stage IIb Hodgkin’s lymphoma with risk factors or at Stage III/IV. Sign up for our daily news round-up!
Pharmaceutical Technology
JULY 4, 2025
Go deeper with GlobalData Reports LOA and PTSR Model - Denosumab Biosimilar in Bone Metastasis Reports LOA and PTSR Model - Denosumab Biosimilar in Chemotherapy Effects Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Pharmaceutical Technology
JULY 7, 2025
Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated. Give your business an edge with our leading industry insights.
Pharmaceutical Technology
JULY 4, 2025
Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with chemotherapy drugs gemcitabine and cisplatin as neoadjuvant treatment, and as a monotherapy after bladder removal surgery. Imfinzi is a major revenue driver for AstraZeneca, generating around $4.7bn in sales in 2024.
Pharmaceutical Technology
JULY 3, 2025
Dizal has received US Food and Drug Administration (FDA) approval for Zegfrovy (sunvozertinib) to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), following progression on or after receiving platinum-based chemotherapy.
Expert insights. Personalized for you.
52 
Let's personalize your content